/
•
•
Context is everything.
Detailed stories on technology startups, business and economic current affairs.
Detailed stories on technology startups, business and economic current affairs.
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
The drugmaker’s reluctance to part with cash may have given it one of the strongest balance sheets in Indian pharma, but investors are increasingly rewarding risk takers.
CEO Rajeev Nannapaneni’s oft-used strategy of mounting patent challenges in the US got the pharma company its latest blockbuster Revlimid. But what after sales fall off a cliff?
A couple of antibiotics that have the potential to change the beleaguered company’s fortunes need a quick infusion of funds to get across the finish line. Can Khorakiwala, the 82-year-old chairman, pull it off?
